AstraZeneca’s datopotamab deruxtecan (Dato-DXd) failed to meet its primary endpoint of overall survival in a Phase 3 breast cancer trial, but the drug continues to show potential in treating lung cancer. The drug did achieve its primary endpoint in the breast cancer trial for progression-free survival and also demonstrated improvement in patient-reported outcomes.
Novartis’ Kesimpta (ofatumumab) demonstrated sustained efficacy in treating relapsing multiple sclerosis (RMS) for up to six years, leading to less disability and disease progression compared to switching from Aubagio (teriflunomide). This data was presented at the European Committee for Treatment and Research in Multiple Sclerosis. The FDA also approved Novartis’ Kisqali (ribociclib) for adjuvant treatment of high-risk early breast cancer.
BriaCell Therapeutics’ stock surged on Wednesday after the company announced encouraging overall survival data from its Phase 2 clinical trial of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) for late-stage metastatic breast cancer. The data revealed a significant improvement in survival compared to previously reported findings and similar patients treated with other methods.
Princess Kate’s recent video message about her cancer journey resonates deeply with Esther, a breast cancer survivor who shares her own experiences. The article explores the emotional and physical challenges that continue long after treatment, highlighting the importance of kindness, compassion, and patience for those who have undergone cancer treatment.
Relay Therapeutics announced positive interim data for its drug candidate RLY-2608 in treating patients with PI3Kα-mutated, HR+, HER2- breast cancer. The data showed clinically meaningful progression-free survival and a high clinical benefit rate in patients receiving RLY-2608 in combination with fulvestrant. The drug was generally well-tolerated, and the company plans to pursue regulatory approval for lirafugratinib in cholangiocarcinoma.
Elle Macpherson, the iconic supermodel of the 1980s, has revealed that she was diagnosed with breast cancer seven years ago. In her new memoir, ‘Elle’, she details her decision to reject conventional treatments like surgery and chemotherapy in favor of a holistic approach.
ICanServe Foundation, a breast cancer awareness advocacy group, is celebrating its 25th anniversary with a unique fundraiser auction called ‘The Pink Room’. The event features 25 renowned Filipino artists who have each designed a custom Nike Air Force (AF1) Triple White shoe, which will be auctioned off on September 14th. Proceeds from the auction will support ICanServe’s efforts to provide treatment, education, and early detection programs for breast cancer patients.
A Black woman shares her harrowing experience with breast cancer, highlighting the systemic biases and lack of awareness within the healthcare system that disproportionately impact Black patients. From misdiagnosis to inadequate treatment, her journey is a powerful testament to the urgent need for inclusivity in clinical research, medical training, and healthcare practices.
Scientists are using organoids, miniature versions of mammary glands grown in a lab, to explore the evolution of milk production across diverse mammal species. These 3D models offer insights into tissue regeneration, breast cancer development, and the biology of lactation, paving the way for advancements in medicine and agriculture.
A large study suggests that women with breast cancer who undergo a double mastectomy do not have a better chance of survival than those who have only the affected breast or the tumor removed. While double mastectomies significantly reduce the risk of developing cancer in the remaining breast, the study found no difference in overall death rates between the surgical groups.
